^
    Back
    Association details:
    Biomarker:PD-L2 overexpression
    Cancer:Acute Myelogenous Leukemia
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ASH 2019
    Title:

    Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

    Published date:
    11/06/2019
    Excerpt:
    ...we did observe high PD-L2 protein expression in AML cells resistant (the 7 with progressive disease) to HMA/PD-L1 inhibition...
    Secondary therapy:
    azacitidine
    DOI:
    10.1182/blood-2019-128601